The correlation between PD-1/PD-L1 status and prognosis suggests that immunotherapy targeting PD-L1/PD-1 might indeed be effective in treating advanced MTC under some circumstances. The gene discussed is CD274; the disease is medullary thyroid gland carcinoma.